Rekah Pharmaceutical Industry Stock Working Capital
REKA Stock | ILA 1,392 9.00 0.64% |
Rekah Pharmaceutical Industry fundamentals help investors to digest information that contributes to Rekah Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Rekah Stock. The fundamental analysis module provides a way to measure Rekah Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Rekah Pharmaceutical stock.
Rekah |
Rekah Pharmaceutical Industry Company Working Capital Analysis
Rekah Pharmaceutical's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Rekah Pharmaceutical Working Capital | 156 M |
Most of Rekah Pharmaceutical's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Rekah Pharmaceutical Industry is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
Competition |
Based on the company's disclosures, Rekah Pharmaceutical Industry has a Working Capital of 156 M. This is 63.35% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The working capital for all Israel stocks is 89.45% higher than that of the company.
Rekah Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Rekah Pharmaceutical's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Rekah Pharmaceutical could also be used in its relative valuation, which is a method of valuing Rekah Pharmaceutical by comparing valuation metrics of similar companies.Rekah Pharmaceutical is currently under evaluation in working capital category among its peers.
Rekah Fundamentals
Return On Equity | 0.0222 | |||
Return On Asset | 0.0208 | |||
Profit Margin | 0.01 % | |||
Operating Margin | 0.05 % | |||
Current Valuation | 316.92 M | |||
Shares Outstanding | 11.41 M | |||
Shares Owned By Insiders | 37.27 % | |||
Shares Owned By Institutions | 42.66 % | |||
Price To Book | 1.11 X | |||
Price To Sales | 0.63 X | |||
Revenue | 263.95 M | |||
Gross Profit | 65.16 M | |||
EBITDA | 36.2 M | |||
Net Income | 6.62 M | |||
Cash And Equivalents | 31.61 M | |||
Cash Per Share | 2.77 X | |||
Total Debt | 101.23 M | |||
Debt To Equity | 1.01 % | |||
Current Ratio | 1.99 X | |||
Book Value Per Share | 14.39 X | |||
Cash Flow From Operations | 21.17 M | |||
Earnings Per Share | 0.32 X | |||
Number Of Employees | 399 | |||
Beta | 0.0605 | |||
Market Capitalization | 193.93 M | |||
Total Asset | 437.09 M | |||
Retained Earnings | 49 M | |||
Working Capital | 156 M | |||
Current Asset | 246 M | |||
Current Liabilities | 90 M | |||
Z Score | 0.6 | |||
Annual Yield | 0.05 % | |||
Net Asset | 437.09 M | |||
Last Dividend Paid | 0.87 |
About Rekah Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Rekah Pharmaceutical Industry's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rekah Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rekah Pharmaceutical Industry based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Rekah Stock
Rekah Pharmaceutical financial ratios help investors to determine whether Rekah Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Rekah with respect to the benefits of owning Rekah Pharmaceutical security.